Adc Therapeutics SA Stock News

ADC Therapeutics SA ( ADCT ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Nicole Riley Ameet Mallik - CEO & Director Mohamed Zaki - Chief Medical Officer Jose Carmona - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Jenna Li - Jefferies LLC, Research Division Leonid Timashev - RBC Capital Markets, Resear...

Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026 Updated data from Phase 2 IIT of ZYNLONTA®  plus rituximab in patients with r/r follicular lymphoma presented at the 22nd International Workshop on Non-Hodgkin Lymphoma Recent financing supports expansion of ZYNLONTA in anticipation of 2L+ DLBCL launch with strengthened bala...

LAUSANNE, Switzerland , Nov. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, November 10, 2025, at 8:30 a.m. EST to report financial results for the third quarter of 2025 and provide operational updates.

LAUSANNE, Switzerland , Oct. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in three upcoming investor conferences in November: Stephens Biotechnology Virtual Fireside Chats 2025Date: November 3, 2025 Presentation Time: 12:00 p.m. ET Format: Fireside ChatSpeake...

LAUSANNE, Switzerland , Oct. 13, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $60.0 million private investment in public equity ("PIPE") financ...

LAUSANNE, Switzerland , Oct. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 162,000 of the Company's common shares to four new employees on October 1, 2025 (each, a "Grant"). The Grants were offered as ma...

LAUSANNE, Switzerland , Sept. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 29,700 of the Company's common shares to two new employees on September 2, 2025 (each, a "Grant").

LAUSANNE, Switzerland , Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:10 a.m. ET. A webcast of the pres...